{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:58:09Z","timestamp":1785491889803,"version":"3.56.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma. MF is typically managed with narrowband ultraviolet B (NB-UVB) or psoralen plus ultraviolet A (PUVA) phototherapy. However, comparative data on their efficacy remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the treatment outcomes of NB-UVB and PUVA in MF and to identify clinical and demographic predictors of response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective cohort study of 33 patients with biopsy-proven MF treated with NB-UVB or PUVA between 2007 and 2024 in the dermatology department at the Sandwell and West Birmingham Hospitals National Health Service Trust. Statistical analysis was performed using Microsoft Excel version 2023 and R version 2023.03.1 + 446.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 33 patients (median age 58 years), 26 (79%) received NB-UVB, 5 (15%) PUVA and 2 (6%) both. Complete remission was achieved in 15 cases (45%) and partial remission in 15 (45%), with 3 (9%) showing no response. Patients with hypopigmented MF had significantly better outcomes than those with hyperpigmented MF (P = 0.02). Advanced stage at treatment initiation was associated with poorer outcomes (P = 0.009). No significant difference was observed in response by sex, age or type of phototherapy. Phototherapy was well tolerated, with adverse effects in only three patients (9%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>NB-UVB and PUVA are effective and well tolerated for the treatment of MF. Hypopigmented variants and \u00adearly-disease stage predicted better outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/skinhd\/vzag039","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T12:38:07Z","timestamp":1774355887000},"page":"454-458","source":"Crossref","is-referenced-by-count":0,"title":["Narrowband ultraviolet B and psoralen plus ultraviolet A\u00a0phototherapy treatment for mycosis fungoides: a 17-year retrospective cohort study in a university teaching hospital, 2007\u201324"],"prefix":"10.1093","volume":"6","author":[{"given":"Thandiwe","family":"Banda","sequence":"first","affiliation":[{"name":"Birmingham Skin Centre, Birmingham City Hospital , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5054-1225","authenticated-orcid":false,"given":"Kashini","family":"Andrew","sequence":"additional","affiliation":[{"name":"Birmingham Skin Centre, Birmingham City Hospital , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0111-1231","authenticated-orcid":false,"given":"Danning","family":"Li","sequence":"additional","affiliation":[{"name":"Birmingham Skin Centre, Birmingham City Hospital , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udoka","family":"Ogbuneke","sequence":"additional","affiliation":[{"name":"Birmingham Skin Centre, Birmingham City Hospital , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husain","family":"Alqari","sequence":"additional","affiliation":[{"name":"Birmingham Skin Centre, Birmingham City Hospital , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"McNeil","sequence":"additional","affiliation":[{"name":"Birmingham Skin Centre, Birmingham City Hospital , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirtha","family":"Rajasekaran","sequence":"additional","affiliation":[{"name":"Birmingham Skin Centre, Birmingham City Hospital , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"2026073105073495500_vzag039-B1","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.3390\/cancers12102921","article-title":"Epidemiology of cutaneous T-cell lymphomas: a systematic review and meta-analysis of 16,953 patients","volume":"12","author":"Dobos","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026073105073495500_vzag039-B2","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.3390\/cancers13081931","article-title":"Mycosis fungoides and S\u00e9zary syndrome: an integrative review of the pathophysiology, molecular drivers, and targeted therapy","volume":"13","author":"Garc\u00eda-D\u00edaz","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026073105073495500_vzag039-B3","doi-asserted-by":"crossref","first-page":"1298296","DOI":"10.3389\/fonc.2023.1298296","article-title":"Effectiveness and tolerability of chlormethine gel for the management of mycosis fungoides: a multicenter real-life evaluation","volume":"13","author":"Alberti-Violetti","year":"2023","journal-title":"Front Oncol"},{"key":"2026073105073495500_vzag039-B4","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and S\u00e9zary syndrome: clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"2026073105073495500_vzag039-B5","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"2026073105073495500_vzag039-B6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/2013.jamadermatol.541","article-title":"Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides","volume":"149","author":"Lessin","year":"2013","journal-title":"JAMA Dermatol"},{"key":"2026073105073495500_vzag039-B7","doi-asserted-by":"crossref","first-page":"113343","DOI":"10.1016\/j.ejca.2023.113343","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome \u2013 update 2023","volume":"195","author":"Latzka","year":"2023","journal-title":"Eur J Cancer"},{"key":"2026073105073495500_vzag039-B8","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"key":"2026073105073495500_vzag039-B9","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/bjd.21669","article-title":"British Association of Dermatologists and British Photodermatology Group guidelines for narrowband ultraviolet B phototherapy 2022","volume":"187","author":"Goulden","year":"2022","journal-title":"Br J Dermatol"},{"key":"2026073105073495500_vzag039-B10","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1001\/jamadermatol.2018.5204","article-title":"Comparison of narrowband UV-B with psoralen\u2013UV-A phototherapy for patients with early-stage mycosis fungoides: a systematic review and meta-analysis","volume":"155","author":"Phan","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2026073105073495500_vzag039-B11","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/phpp.12383","article-title":"Phototherapy as a first-line treatment for early-stage mycosis fungoides: the results of a large retrospective analysis","volume":"34","author":"Nikolaou","year":"2018","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"2026073105073495500_vzag039-B12","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.clml.2017.06.015","article-title":"Bath psoralen\u2013ultraviolet A and narrowband ultraviolet B phototherapy as initial therapy for early-stage mycosis fungoides: a retrospective cohort of 267 cases at the University of Toronto","volume":"17","author":"Almohideb","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026073105073495500_vzag039-B13","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1468-3083.2006.01557.x","article-title":"UVB in the management of early stage mycosis fungoides","volume":"20","author":"Pavlotsky","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026073105073495500_vzag039-B14","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/phpp.12873","article-title":"Nb-UVB and PUVA therapy in treating early stages of mycosis fungoides: a single-center cross-sectional study","volume":"39","author":"Zengarini","year":"2023","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"2026073105073495500_vzag039-B15","first-page":"e21231","article-title":"Clinical patterns and treatment response of patients with mycosis fungoides a retrospective study","volume":"14","author":"Alojail","year":"2022","journal-title":"Cureus"},{"key":"2026073105073495500_vzag039-B16","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1067\/mjd.2002.120911","article-title":"Narrowband UVB phototherapy for early-stage mycosis fungoides","volume":"47","author":"Gathers","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"2026073105073495500_vzag039-B17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1600-0781.2012.00662.x","article-title":"Phototherapy for hypo\u00adpigmented mycosis fungoides in Asians","volume":"28","author":"Wongpraparut","year":"2012","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"2026073105073495500_vzag039-B18","doi-asserted-by":"crossref","first-page":"645","DOI":"10.25259\/IJDVL_555_19","article-title":"Phototherapy as a treatment of early-stage mycosis fungoides and predictive factors for disease recurrence: a 17-year retrospective study","volume":"87","author":"Rattanakaemakorn","year":"2021","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"2026073105073495500_vzag039-B19","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/phpp.12872","article-title":"Risk of skin cancers in mycosis fungoides patients receiving PUVA therapy: a real-life experience from a single tertiary center","volume":"39","author":"Do\u011fan","year":"2023","journal-title":"Photodermatol Photoimmunol Photomed"}],"container-title":["Skin Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/6\/4\/454\/68494504\/vzag039.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/6\/4\/454\/68494504\/vzag039.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:07:39Z","timestamp":1785488859000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/skinhd\/article\/6\/4\/454\/8704421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":19,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,6,9]]},"published-print":{"date-parts":[[2026,7,31]]}},"URL":"https:\/\/doi.org\/10.1093\/skinhd\/vzag039","relation":{},"ISSN":["2690-442X"],"issn-type":[{"value":"2690-442X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,6,9]]}}}